bioRxivBiophysicsPreprint
The hypertrophic cardiomyopathy mutation G768R makes cardiac myosin a high duty ratio motor
Divya PathakiD, T Ozturk Dalpe, Aminah DawoodiD, Matthew Carter ChildersiD, Michael RegnieriD, James A. SpudichiD, Chao LiuiD, Kathleen M. RuppeliD
Abstract
{beta}-cardiac myosin is the primary motor protein in the human heart responsible for force generation by converting chemical energy from ATP hydrolysis to mechanical work. It binds actin, produces force through its powerstroke, and releases actin, and must complete this cycle several times a second within each heartbeat. Like other muscle myosins, cardiac myosin has a low duty ratio of [~]5%, the fraction of time in the actin-bound force-producing state. Here we present a hypertrophic cardiomyopathy (HCM) causing mutation, G768R, that increases cardiac myosins duty ratio to >60%, an unprecedented >10x increase unmatched by any previously studied muscle myosin mutation. In recombinantly expressed human {beta}-cardiac myosin subfragment-1 (sS1), G768R dramatically decreases the load-sensitive actin-detachment rate and step size of single molecules measured by optical tweezers. The [~]15x longer actin-bound time combined with only a modest change in overall ATPase rate predicts a duty ratio of >60%. Motility velocity is also severely slowed, as expected given the long bound time and decreased step size. All-atom molecular dynamic simulations of the pre-powerstroke and post-rigor states predict that the mutation alters lever arm priming and reduces ADP pocket opening, providing a possible structural mechanism to corroborate the experimental observations. Finally, ATPase experiments on 2-headed heavy meromyosin (HMM) constructs suggest that G768R destabilizes the autoinhibited state of myosin. Our findings of high duty ratio and reduced autoinhibition provide molecular mechanisms of cardiac hypercontractility and impaired relaxation. A muscle myosin in the heart that stays bound to actin for over half its period is bound to have significant functional and clinical consequences.
- organism: human
- assay: proteomics
- research focus: cell signaling & trafficking
- approach: experimental assay
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A myosin hypertrophic cardiomyopathy mutation disrupts the super-relaxed state and boosts contractility by enhanced actin attachment
Robert C. Cail, Bipasha Barua, … E. Michael Ostap·Proceedings of the National Academy of SciencesPeer-reviewed·Dec 24, 2025
- Hypertrophic cardiomyopathy β-cardiac myosin mutation (P710R) leads to hypercontractility by disrupting super-relaxed state: multiscale measurements and computational modeling
A. S. Vander Roest, C. Liu, … D. Bernstein·bioRxiv·Nov 10, 2020
- Mutations in the catalytic domain of human β-cardiac myosin that cause early onset hypertrophic cardiomyopathy significantly increase the fundamental parameters that determine ensemble force and velocity
Arjun S Adhikari, Kristina B Kooiker, … Kathleen M Ruppel·bioRxiv·Aug 9, 2016
- Biophysical properties of human β-cardiac myosin with converter mutations that cause hypertrophic cardiomyopathy
Masataka Kawana, Saswata S Sarkar, … James Spudich·bioRxiv·Jul 26, 2016
- The molecular basis of hypercontractility caused by the hypertrophic cardiomyopathy mutations R403Q and R663H
S. S. Sarkar, D. V. Trivedi, … J. A. Spudich·bioRxiv·Feb 7, 2019
- Myosin motor domains carrying mutations implicated in early or late onset Hypertrophic Cardiomyopathy have similar properties
C. D. Vera, C. A. Johnson, … L. A. LEINWAND·bioRxiv·Aug 10, 2019